Oncolytic Virotherapies in Ovarian Cancer and NSCLC with Genelux CEO Thomas Zindrick скачать в хорошем качестве

Oncolytic Virotherapies in Ovarian Cancer and NSCLC with Genelux CEO Thomas Zindrick

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Thomas Zindrick, President and CEO of Genelux Corporation, an immuno-oncology company focused on developing immunotherapeutics, specifically oncolytic virotherapies, in cancers including ovarian cancer and non-small cell lung cancer (NSCLC). Thomas has served as Chairman since July 2021 and as a Board member, President and CEO since 2014. He brings more than 30 years of executive experience in the ife sciences and biotechnology. He also currently serves as Executive Chair of Aeromics, Inc., a clinical-stage company focused on ischemic stroke, and previously, held board roles at Amitech Therapeutic Solutions and DNX Biopharmaceuticals. He spent 16 years at Amgen, including as Vice President, Associate General Counsel and Chief Compliance Officer. Thomas began his career as an attorney at The Dow Chemical Company. He holds a JD from the University of Illinois College of Law and a BA in Biology from North Central College. Tune in to learn about how oncolytic virotherapies are being developed for challenging cancers, and improving trial participation, communication and patient-centered approaches in advancing cancer research. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter:   / xtalks   Instagram:   / xtalks   Facebook:   / xtalks.webinars   LinkedIn:   / xtalks-webconferences   YouTube:    / xtalkswebinars